Dr Stavros has over 30 years of industry experience in the design, implementation, management and regulatory submission of nonclinical drug development from lead optimization to market approval. She has extensive knowledge and expertise in strategic nonclinical development program design and execution, GLP compliance, clinical bioanalysis and pharmacokinetic assessment, contract research organization (CRO) selection and management, and in the writing and submission of the nonclinical regulatory documents (foreign and domestic). Dr Stavros has personally taken a small molecule from target identification, through lead optimization, into first in man studies and on to market approval.
Prior to joining Renibus Therapeutics Dr. Stavros was VP of Nonclinical Development at ZS Pharma where she had sole responsibility for the nonclinical development of Lokelma.